Loading clinical trials...
Loading clinical trials...
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatm...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Avidity Biosciences, Inc.
NCT07486934 · Myotonic Dystrophy Type 1 (DM1), DM1, and more
NCT06809049 · Myotonic Dystrophy, Congenital, Myotonic Dystrophy, Type 1 (DM1), and more
NCT06300307 · Myotonic Dystrophy 1
NCT06523400 · Myotonic Dystrophy
NCT06844214 · Myotonic Dystrophy
University of California, Los Angeles (UCLA)
Los Angeles, California
Stanford University
Stanford, California
University of Colorado
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions